CAMBRIDGE, England--(BUSINESS WIRE)--Horizon Discovery™ (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has signed a worldwide distribution agreement with Haplogen GmbH (Haplogen), with immediate effect. Under the terms of the agreement customers can now access, directly from Horizon, Haplogen’s Haploid Gene Trap Mutant Collection of isogenic human cell lines deficient for the expression of single genes. This agreement represents the first time that Horizon will be distributing another company’s products, recognizing Horizon’s past success in penetrating the global model cell lines market.
Help employers find you! Check out all the jobs and post your resume.
